3D bioprinting technology capable of creating living human tissue cells on demand Their mission is to improve the predictive accuracy of pre-clinical drugs by providing pharmaceutical companies and researchers with 3D human tissue they can to test new therapeutics. In the long term this can lead to full organ printing.   Bottom line -  Aspect’s technology has the potential to drive a fundamental shift in the pharmaceutical industry by speeding the time it takes companies release new drugs. Potential to reduce the use of laboratory animals and waste involved with new drugs productions. The Bioprinting space is heating up with new companies testing printed blood and other life science breakthroughs.